Ampulla of Vater Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An invasive carcinoma with glandular differentiation arising from the ampulla of Vater. Signs and symptoms include jaundice, abdominal pain, anorexia, nausea, vomiting, and weight loss. 
Ampulla of vater adenocarcinomas most frequently harbor alterations in KRAS, TP53, CDKN2A, SMAD4, and APC .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in ampulla of vater adenocarcinoma .
There are 4 clinical trials for ampulla of vater adenocarcinoma, of which 3 are open and 1 is completed or closed. Of the trials that contain ampulla of vater adenocarcinoma as an inclusion criterion, 1 is phase 1 (1 open) and 3 are phase 2 (2 open).
G6PD is the most frequent gene inclusion criterion for ampulla of vater adenocarcinoma clinical trials .
5b1, ascorbic acid, and docetaxel are the most common interventions in ampulla of vater adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.